TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06220591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior trunk block
Description: The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clavipectoral fascial plane block
Description: The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle.
Study: NCT05757141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosigotifator
Description: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosigotifator
Description: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosigotifator
Description: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosigotifator
Description: Oral Use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosigotifator
Description: Oral Use
Study: NCT05456191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD administered under fasting conditions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Nilotinib 300 mg BID administered under fasting conditions.
Study: NCT06140836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Specified dose on specified days
Study: NCT04753658

Intervention type: DRUG
Intervention: lorlatinib
Description: Oral
Study: NCT05264376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Body Project
Description: The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
Study: NCT05515588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 (C-14)
Description: BI 690517 (C-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 (C-14)
Description: BI 690517 (C-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: BI 690517
Study: NCT06186336

Intervention type: OTHER
Intervention: Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
Description: Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study.
Study: NCT04943445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.
Description: Consolidation immunotherapy
Study: NCT06216548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care and Enhanced Primary Care
Description: Usual Care: Interdisciplinary complex care teams help coordinate appointments, facilitate communication between the many specialist providers involved in the child's care, support families, assist with practical needs, and are available as a resource (as consultants) for Primary Care Physicians (PCPs) to care for Children with Medical Complexity (CMC). The complex care teams in tertiary care children's hospital is the focus for providing comprehensive care for CMC.~Enhanced Primary Care: The E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. A team of telehealth experts will help PCPs in using telehealth in their practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Primary Care
Description: The intervention has the following components: (A) The staff of the E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. (B) The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. (C) A team of telehealth experts will help PCPs in using telehealth in their practice.
Study: NCT06353256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual postpartum care
Description: Usual clinical and educational postpartum care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual postpartum care + community health worker intervention
Description: participants will receive routine care and also community health worker support and visits.
Study: NCT05703698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Psychosis
Description: CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
Study: NCT06116968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: 5-20mg
Study: NCT05184062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg AZD7442 IV
Description: Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 600mg placebo IV
Description: Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
Study: NCT06678243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smiling instead of Smoking
Description: Participants randomized to the treatment condition will use the Smiling instead of Smoking (SiS) smartphone app. This app delivers and guides participants through two types of content to help them during their quit attempt: (1) positive psychology content (i.e., happiness habit-building exercises, happiness boost activity, and science-based information on the relevance of positive psychology activities) designed to help nondaily smokers maintain positive affect while they go through the process of smoking cessation; and (2) traditional behavioral smoking cessation content to guide their quit process based on US Clinical Practice Guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide
Description: Participants randomized to the control condition will use the National Cancer Institute (NCI)'s QuitGuide (QG) smartphone app. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based).
Study: NCT06694441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Exposure
Description: The intervention in this study will involve 28 (+4) days of daily exposure to bright light (BL) for two 60-minute sessions (morning and afternoon). For the intervention, we will use Re-Timer® light glasses emitting light with an intensity of 230μW/cm2 (\~500lux) with a green blue 500nm dominant wavelength (between 480-520nm). Light with these characteristics has been shown effective in suppressing melatonin levels supporting their potential to exert effects on other biological non-visual functions associated with exposure to light relevant for this study. Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the control group will wear for two 60-minute sessions (morning and afternoon) customized dim-red light (RL) control Re-Timer® light glasses (wavelength peak at 632nm, light intensity \< 3 lux).
Study: NCT06687148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual manipulation
Description: The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
Study: NCT06056440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group will only receive their usual treatment program for the 12-week duration of the study.
Study: NCT06155656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein concentrate
Description: Ingestion of a soup containing 25 g of protein from pea protein concentrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein isolate
Description: Ingestion of a soup containing 25 g of protein from pea protein isolate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein extrudate
Description: Ingestion of a soup containing 25 g of protein from pea protein extrudate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Ingestion of a soup containing 25 g of protein from whey protein
Study: NCT05148442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI322
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody
Study: NCT04137653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel+carboplatin
Description: Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel+carboplatin
Description: Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
Study: NCT05093907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEY1107
Description: Administer once daily, PO, 3-week continuous dose.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.
Study: NCT05566431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICP
Description: The intervention is a management protocol that includes ICP monitoring for children with severe traumatic brain injury

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CREVICE
Description: The intervention is a management protocol that is based on imaging and clinical examinations without ICP monitoring for children with severe traumatic brain injury
Study: NCT06378749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreCharge
Description: PreCharge is an intervention for Hereditary Cancer Syndrome Previvors that administers brief assessments and uses multivariate algorithms and tailoring technology to provide timely, individualized, bi-directional text messages to improve resilience and coping. The program uses proven approaches to behavior change tailoring to increase resilience by promoting a positive mindset, strong social connections, and a deep sense of meaning and purpose. It will also proactively provide access to online tools prior to medical appointments to address scanxiety (e.g., management of emotion tips; mindfulness meditation; communication scripts; breathing exercises). At any time, users will be able to text a trigger word to indicate that they need extra support and will receive just-in-time assistance via text message.
Study: NCT04902404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First Pathways Game
Description: The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
Study: NCT04837989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Body Project
Description: Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
Study: NCT05973773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS6417
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS6417
Description: oral tablets
Study: NCT04872348

Intervention type: DEVICE
Intervention: OMNI® Surgical System
Description: The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Intervention type: DEVICE
Intervention: OMNI® Surgical System
Description: The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
Study: NCT05976763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06249412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI-E with PEP function activated during the pause
Description: PEP function will be activated during the pause when using the EOVE-70. The PEP function in cmH2O will start at 8 cmH2O; the PEP setting can be decreased or increased at the discretion of the practitioner to optimize. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MI-E without PEP function activated during the pause
Description: The PEP function will not be activated during the pause when using the EOVE-70. The other therapeutic settings (positive pressure, negative pressure, inspiratory time, expiratory time and pause time) will be set individually for each patient by an experienced physiotherapist in order to reach the best clinical efficacy (usual clinical care)
Study: NCT05976763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD
Study: NCT06687148

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: The participants will receive one session of sham manipulation if in the sham group. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation, the physiotherapist will pretend to execute a thrust.
Study: NCT05976763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD
Study: NCT06697431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Patients who fulfill the eligibility criteria a will be randomized 1:1 to receive either~1. IVIG 2g/kg administered in 10-12 hours as per local standard of care (standard treatment) OR~2. Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day (investigational treatment)~Patients showing fever, between 36 hours and 72 hours from the end of first line treatment will be considered failures. Failures from the investigational treatment arm will receive a dose of IVIG and they will drop from the study.~Children who remained afebrile between the 36th and 72nd hour will be considered as responders, and they will proceed into the study.~Patients in the standard treatment arm will continue ancillary treatment and follow-up .~Patients in the investigational treatment arm will enter the tapering phase.
Study: NCT06520852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group using artificial intelligence tools in addition to traditional tools in preparing educational materials
Description: Students in the intervention group used AI tools in addition to tools such as books, journals, and websites.